COST-EFFECTIVENESS AND COST-UTILITY OF GENOTHERAPEUTIC DRUG NEOVASCULGEN IN TREATMENT OF CHRONIC LOWER LIMB ISCHEMIA
Pl-VEGF165 (Neovasculgen) is a new genotherapeutic drug for treatment of chronic lower limb ischemia. It is registered in Russia and underwent effectiveness assessment in clinical trial. Objective of this study is to report results of the economical modeling study to compare long-term effectiveness...
Main Authors: | S. L. Plavinsky, P. I. Shabalkin |
---|---|
Format: | Article |
Language: | Russian |
Published: |
Remedium Group LLC
2017-11-01
|
Series: | Медицинский совет |
Subjects: | |
Online Access: | https://www.med-sovet.pro/jour/article/view/2179 |
Similar Items
-
The Experience of Using “Neovasculgen” in the Complex Treatment of Patients with Critical Lower Limb Ischemia
by: Mikhail M. Vinokurov, et al.
Published: (2020-09-01) -
Does the new vascular management of acute limb ischemia have effective results with lower treatment costs
by: Haris Vukas, et al.
Published: (2019-08-01) -
Saving the Foot from “Bliss of Ignorance”: Tackling Missed Acute Lower Limb Ischemia
by: Ajay Kumar Dabas, et al.
Published: (2021-01-01) -
Pharmacoeconomic analysis of naft idrofuryl in patients with chronic obliterating diseases of lower limb arteries
by: A. E. Cheberda, et al.
Published: (2018-05-01) -
Lower limb ischemia and multiple organ dysfunction syndrome following wasp Sting
by: Jeyakanth T, et al.
Published: (2015-05-01)